The Future of Surgery: Anticipating Breakthroughs in the Operating Theater by 2050

Surgery has historically been associated with significant risks, including high mortality rates, postoperative complications, and human error. For instance, studies suggest that medical errors contribute to more than 400,000 deaths in the United States alone every year, making it a leading cause of preventable harm in healthcare.

But surgery is evolving dramatically, moving from a field of high risks and mortality to one empowered by technological advancements. Artificial intelligence (AI) is at the forefront of this transformation, specifically through two emerging forms: Software AI, which supports digital and administrative processes, and robotic AI, used directly in surgical procedures. Together, these innovations are reshaping the operating room, making surgeries safer and more efficient.

Caresyntax Connected Surgery Program’s streamlined workflows and real-time OR visibility reduce delays and complications in ORs by offering real-time decision support and vendor-neutral device integration. Additionally, software-based technology can reduce both initial investment and total ownership costs by as much as 50%.

Thomas Hagemeijer, Healthcare Lead at TLGG Consulting, highlights surgery’s economic impact, stating that “surgery represents more than 30% of global healthcare spending (over $3 trillion annually).” Despite this, Hagemeijer notes that surgical technology has seen only marginal advancements over recent decades. Already by 2030, however, he anticipates substantial growth in areas like robotics, brain-computer interfaces (BCIs), and other groundbreaking technologies. For instance, the global BCI market, he predicts, could reach $6.2 billion, growing at an unprecedented rate.

There are additional predictions that there is a 50% chance or better that AI will outperform physicians (and surgeons) by 2050. In many ways, this includes refinements of what we’ve already seen from the introduction of AI in surgery.

Caresyntax’s work with Assistance Publique-Hôpitaux de Paris (integrating within existing hospital infrastructure and enabling delivery of novel applications) shows how AI and software platforms reduce operational inefficiencies.

What does the future hold?

AI is already making improvements in surgery. The Caresyntax platform is improving decision-making and reducing inefficiencies in real-time, by ensuring that surgeons have access to critical data during surgery. This isn’t only improving patient safety but also reduces admin tasks and burdens, allowing the surgical team to focus on patients

Hagemeijer suggests that Software AI is poised to deliver the most immediate impact on surgery compared to robotic AI.

"Why? Because Software AI, used in both non-clinical and clinical products throughout the surgical process, can solve immediate problems like staff shortages, reducing paperwork, and improving safety and quality," he explains. "The technology is flexible and advanced enough to make an impact right away."

Robotic AI, however, is currently used in less than 1% of surgeries worldwide and may take decades to achieve broader adoption. Hagemeijer foresees convergence between Software AI and robotic AI, creating hybrid systems capable of transforming surgical outcomes.

Better tools — better surgery

Emerging technologies like BCIs and robotics can improve surgery across all levels of an operation by reducing human error, improving precision, and enhancing outcomes. Here are just some improvements it can make:

Cardiovascular surgery: the heart and blood vessels

Robotic arms enable precision in procedures like valve replacements, reducing risks to surrounding tissues.

As a result, patients experience faster recovery times and fewer complications. By 2050, AI-driven robotic systems will assist or even perform entire procedures with minimal human intervention.

Additionally, a new field of “predictive medical data mining” will provide early warnings, even before people develop any symptoms, allowing doctors to intervene timely in case of any issues and improve screening processes. This data, previously obtained during check-ups, will now be fully available to physicians from sensors on/around our “smart” bodies.

Orthopedic surgery: bones, joints, and muscles

In orthopedic surgeries, robotic systems can guide placement during joint replacements. This increases the accuracy of procedures like spinal fusions improving long-term patient outcomes.

By 2050, nanorobots will deliver targeted drugs to damaged bones and joints, accelerating healing. Additionally, the existence of AI will likely eliminate the need for traditional orthopedic surgeries, transforming them in a way that requires minimal intervention.

Neurosurgery: the brain, spine, and nervous system

Neurosurgery, which requires extreme precision, is already changed by robotics, enabling minimally invasive procedures for spine and brain surgeries. Robotic tools can make tiny incisions, reducing damage to healthy tissue. BCIs could restore lost functions for patients through robotic prosthetics, offering life-changing capabilities for those with paralysis, by allowing them to directly control robotic limbs or devices.

Caresyntax, in turn, can aggregate real-time video and patient data, assisting in delicate brain tumor resections. Its platform does so by using surgical data for real-time decision-making and remote collaboration.

Gastrointestinal surgery: the digestive system, including the stomach and intestines

In gastrointestinal surgery, robotic systems already perform minimally invasive tumor removals. By 2050, advanced tools could offer greater accuracy, faster recovery times, and non-invasive control for internal devices through BCIs.

Oncology surgery: remove or treat cancerous tumors

As in other surgeries, robotic systems can help surgeons remove tumors precisely, especially in sensitive areas like the lungs, brain, or liver, and minimize the amount of healthy tissue removed, significantly improving patient outcomes.

In 2023, Caresyntax, Relyens, and Intel launched the Connected Surgery program, integrating AI into the operating rooms of the Assistance Publique-Hôpitaux de Paris (APHP) to optimize OR performance and outcomes.

BCIs could also allow surgeons to operate robotic systems using mental commands, especially in procedures requiring split-second decisions. Robots equipped with advanced imaging systems could detect and remove microscopic cancer cells, reducing the chances of cancer returning after surgery.

Risks and limitations

Despite its potential, robotic and AI-driven surgery faces notable risks and limitations.

First of all, robotic systems and BCIs are expensive to develop, purchase, and maintain. Cost remains a significant barrier, limiting access for patients and healthcare facilities.

Training is another hurdle. Surgeons require extensive education to operate robotic systems effectively and, most importantly, safely. Even after training, human error remains a risk, and adapting to new tools in high-risk procedures involves a steep learning curve.

Technical malfunctions also pose risks. Software glitches or hardware failures during surgery could lead to complications, especially in high-risk surgeries. Caresyntax’s Connected Surgery platform integrates fail-safes to reduce risks associated with system downtime.

Caresyntax focuses on streamlining OR procedures to minimize reliance on manual processes. It can reduce unnecessary surgical variations by enabling hospitals to monitor and analyze these variations and provide recommendations to reduce the gaps in surgical practices.

BCIs remain experimental, with ongoing concerns about their reliability and application in high-pressure environments. Ensuring accuracy during critical time-sensitive procedures is essential for wider adoption.

But with each innovation, we move closer to a future where life-saving procedures are safer, less invasive, and more accessible to all.

Regulatory and ethical considerations

Compliance with the FDA in the United States (U.S.) and the EMA in Europe is critical to bringing surgical AI and robotic systems to market. Ensuring compliance with these regulatory bodies involves a thorough review process, transparency, and continuous monitoring to maintain safety standards.

Data privacy and security represent another significant challenge. Protecting patient information under regulations like the Health Insurance Portability and Accountability Act (HIPAA) is mandatory for protecting patient information and GDPR requires advanced encryption methods and stricter access controls.

Caresyntax uses vendor-neutral approach to ensuring data compliance. It’s used solely according to the DSGVO (GDPR) and other national data protection laws. The data is collected in the logfiles of their system and is not connected with other users’ personal data.

Accountability for errors involving AI systems must be addressed. Clear guidelines on who is responsible — whether it be the manufacturer, the surgeon, or the healthcare institution — are important in cases of adverse outcomes.

Caresyntax tracks post-operative outcomes to ensure devices meet safety standards and patient expectations.

The ethical use of data also involves ensuring patient consent. Patients should be informed about how their data will be used and be able to opt out. Ethical data use requires addressing issues of data ownership and control.

A look forward

Ultimately, over the next decades, surgery will transform into a collaborative effort between cutting-edge technology and human expertise. This synergy holds the potential to revolutionize patient care globally, shaping a healthcare system that serves humanity better than ever before.

“By 2050, we are going to see a world where it [healthcare] is going to be commoditised, democratised, and consumerised,” Reenita Das, Healthcare and Life Sciences Partner, Senior Vice President, and the first woman Partner at Frost and Sullivan, said.

Caresyntax has established Value Partnerships with some of the largest hospital systems across Europe including Assistance Publique-Hôpitaux de Paris (APHP) in Paris, France; a large hospital group in Northern Germany; the Hospital Universitario Virgen de la Arrixaca in Murcia, Spain; and Villa Betania Clinic in Rome, Italy. The expansion will continue, with the connection of more ORs across Europe.